In summary, the trifunctional antibodies exhibit the following properties: i) dual tumor-targeting by EGFR and PD-L1 binding to increase tumor selectivity, ii) immune checkpoint inhibition by blocking the PD-1/PD-L1 axis, and iii) potent NK cell-mediated cytotoxicity by CD16a targeting (Figure 6). This evidence concerns the gene EGFR and neoplasm.